ArticleCancers2026

Incidence and Clinical Impact of Endocrinopathy Following First-Line Nivolumab-Plus-Relatlimab Therapy for Metastatic Melanoma.

Julia Reitkopp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.